Tag: MSB

Small cap fallen angels ASX FNP CCV PGL HUM MSB

Can these fallen small cap angels regain their wings?

One of the trickiest aspects of investing is deciding whether a fallen angel will ever fly again. If they do regain their wings, the rewards of buying in at distressed levels can be enormous. But a...
ASX stocks short squeeze shorted

What are the ASX stocks vulnerable to a ‘short squeeze’?

Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly ...
Mesoblast ASX MSB Oncologic Drugs Advisory Committee ODAC remestemcel-L RYONCIL

Mesoblast’s lead drug candidate achieves major regulatory milestone after US FDA vote

Shares in Australian biotech midcap Mesoblast (ASX: MSB) have hit their highest point in more than six years today, following the US Food and Drug Administration’s Oncological Drugs Advisory Committee...
ASX biotech stocks COVID-19 life science

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Natural...
Mesoblast ASX MSB revenues remestemcel-L Ryoncil GvHD

Mesoblast sees strong revenue growth as maintains busy clinical program with upcoming Ryoncil launch

In an interim performance update focusing on the past nine months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress ...
Mesoblast ASX MSB remestemcel-L drug COVID-19 survival rates ventilator

Mesoblast’s remestemcel-L drug could boost COVID-19 survival rates

Mesoblast’s (ASX: MSB) advanced remestemcel-L drug could potentially boost the survival rate of critically ill COVID-19 patients who have developed acute respiratory distress syndrome, with initial re...
Mesoblast acute respiratory distress syndrome ARDS COVID-19 ASX MSB FDA

Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress

Regenerative medicine company Mesoblast (ASX: MSB) has received US Food and Drug Administration Investigational New Drug (IND) clearance for its remestemcel-L treatment to be used in COVID-19 patients...
Mesoblast COVID-19 coronavirus lung disease allogeneic mesenchymal stem cell ASX MSB

Mesoblast to trial anti-inflammatory infusions in COVID-19 patients with respiratory distress

Mesoblast (ASX: MSB) is the latest ASX company to potentially benefit commercially from the coronavirus global epidemic after revealing it would be evaluating its anti-inflammatory product in COVID-19...
Mesoblast ASX MSB manufacturing agreement Lonza allogeneic cell therapy

Mesoblast signs manufacturing agreement with Lonza, prepares for US launch

Allogeneic cellular medicines company Mesoblast (ASX: MSB) is on track to commence manufacturing of its lead product candidate remestemcel-L courtesy of a manufacturing agreement with Swiss-listed che...